BREAST: TRADE | DFCI 23-355
Trial ID
NCT06001762
Trial Sponsor
Dana-Farber Cancer Institute
The TRADE Study: A Phase 2 Trial to Assess the ToleRability of Abemaciclib Dose Escalation in Patients With Early-Stage HR-positive and HER2-negative Breast Cancer